Combs Andrew
SEC CIK 1825005 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | EVP, Head of Chemistry | 480.1K | $249.6K | — | 4 | 2021-12-13 | 2025-03-25 |
Most active insiders at PRLD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bonita David P | Dir, 10% | $12.50M | — |
| 2 | ORBIMED ADVISORS LLC | Dir, 10% | $12.50M | — |
| 3 | Huang Jane | Pres, CMO | — | — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 10% | — | — |
Combs Andrew made no open-market trades at PRLD in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-27 | 2025-03-25 | PRLD | Prelude Therapeutics Inc | Combs Andrew | Chief Chemistry Off | P - Purchase | $0.69 | +100.0K | 480.1K | +26% | +$69.0K | |
| M | 2024-12-26 | 2024-12-20+ | PRLD | Prelude Therapeutics Inc | Combs Andrew | Chief Chemistry Off | P - Purchase | $1.36 | +63.1K | 377.6K | +20% | +$85.7K |
| D | 2022-04-04 | 2022-03-31 | PRLD | Prelude Therapeutics Inc | Combs Andrew | EVP, Head of Chemistry | M - OptEx | $1.89 | +36.1K | 304.4K | +13% | +$68.2K |
| M | 2021-12-15 | 2021-12-13+ | PRLD | Prelude Therapeutics Inc | Combs Andrew | EVP, Head of Chemistry | P - Purchase | $11.86 | +8,000 | 268.4K | +3% | +$94.9K |
Purchase Sale Sale after option exercise All abbreviations